{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:39:13Z","timestamp":1790786353470,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,4]]},"DOI":"10.7759\/cureus.46455","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T08:52:24Z","timestamp":1696409544000},"source":"Crossref","is-referenced-by-count":7,"title":["Efficacy and Safety Profile of Ticagrelor Versus Clopidogrel in Percutaneous Coronary Intervention (PCI) for Acute Coronary Syndrome (ACS): A Systematic Review and Meta-Analysis"],"prefix":"10.7759","author":[{"given":"Shahzaib","family":"Maqbool","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sajjad","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdur","family":"Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Ebad","family":"Ur Rehman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azeen","family":"Razzaq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani Shivamadhu","family":"Shivamadhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maham","family":"Afzal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faizan","family":"Fazal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jawad","family":"Basit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed Aizaz","family":"Khalid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa575","article-title":"2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation","volume":"42","author":"Collet JP","year":"2021","unstructured":"Collet JP, Thiele H, Barbato E, et al.. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021, 42:1289-367. 10.1093\/eurheartj\/ehaa575","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.09.057","article-title":"ACC\/AHA versus ESC guidelines on dual\u00a0antiplatelet therapy: JACC Guideline Comparison","volume":"72","author":"Capodanno D","year":"2018","unstructured":"Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC\/AHA versus ESC guidelines on dual\u00a0antiplatelet therapy: JACC Guideline Comparison. J Am Coll Cardiol. 2018, 72:2915-31. 10.1016\/j.jacc.2018.09.057","journal-title":"J Am Coll Cardiol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012078","article-title":"Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study","volume":"8","author":"Yun JE","year":"2019","unstructured":"Yun JE, Kim YJ, Park JJ, et al.. Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study. J Am Heart Assoc. 2019, 8:e012078. 10.1161\/JAHA.119.012078","journal-title":"J Am Heart Assoc"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes","volume":"361","author":"Wallentin L","year":"2009","unstructured":"Wallentin L, Becker RC, Budaj A, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009, 361:1045-57. 10.1056\/NEJMoa0904327","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"39","author":"Valgimigli M","year":"2018","unstructured":"Valgimigli M, Bueno H, Byrne RA, et al.. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018, 39:213-60. 10.1093\/eurheartj\/ehx419","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrcardio.2014.104","article-title":"Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI","volume":"11","author":"Levine GN","year":"2014","unstructured":"Levine GN, Jeong YH, Goto S, et al.. Expert consensus document: World Heart Federation expert consensus statement on antiplatelet therapy in East Asian patients with ACS or undergoing PCI. Nat Rev Cardiol. 2014, 11:597-606. 10.1038\/nrcardio.2014.104","journal-title":"Nat Rev Cardiol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suw034","article-title":"Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients","volume":"18","author":"Wang X","year":"2016","unstructured":"Wang X, Xi S, Liu J, Qin L, Jing J, Yin T, Chen Y. Switching between ticagrelor and clopidogrel in patients who underwent percutaneous coronary intervention: insight into contemporary practice in Chinese patients. Eur Heart J Suppl. 2016, 18:F19-26. 10.1093\/eurheartj\/suw034","journal-title":"Eur Heart J Suppl"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2010.10.029","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial","volume":"57","author":"Held C","year":"2011","unstructured":"Held C, Asenblad N, Bassand JP, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery: results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J Am Coll Cardiol. 2011, 57:672-84. 10.1016\/j.jacc.2010.10.029","journal-title":"J Am Coll Cardiol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati A","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, et al.. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009, 339:b2700. 10.1136\/bmj.b2700","journal-title":"BMJ"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang A","year":"2010","unstructured":"Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010, 25:603-5. 10.1007\/s10654-010-9491-z","journal-title":"Eur J Epidemiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad AR","year":"19961","unstructured":"Jadad AR, Moore RA, Carroll D, et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary?. Controlled clinical trials. 19961, 17:1-2. 10.1016\/0197-2456(95)00134-4","journal-title":"Controlled clinical trials"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.22037\/aaem.v11i1.1870","article-title":"Effect of Ticagrelor compared to Clopidogrel on short-term outcomes of COVID-19 patients with acute coronary syndrome undergoing percutaneous coronary intervention; a randomized clinical trial","volume":"11","author":"Arefizadeh R","year":"2023","unstructured":"Arefizadeh R, Moosavi SH, Towfiqie S, Mohsenizadeh SA, Pishgahi M. Effect of Ticagrelor compared to Clopidogrel on short-term outcomes of COVID-19 patients with acute coronary syndrome undergoing percutaneous coronary intervention; a randomized clinical trial. Arch Acad Emerg Med. 2023, 11:e14. 10.22037\/aaem.v11i1.1870","journal-title":"Arch Acad Emerg Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061657","article-title":"P2Y12 inhibitor monotherapy with clopidogrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"9","author":"Chen PW","year":"2020","unstructured":"Chen PW, Feng WH, Ho MY, et al.. P2Y12 inhibitor monotherapy with clopidogrel versus ticagrelor in patients with acute coronary syndrome undergoing percutaneous coronary intervention. J Clin Med. 2020, 9:10.3390\/jcm9061657","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6476777","article-title":"Ticagrelor versus Clopidogrel in patients with severe renal insufficiency undergoing PCI for acute coronary syndrome","volume":"2022","author":"Chen Y","year":"2022","unstructured":"Chen Y, Tu S, Chen Z, et al.. Ticagrelor versus Clopidogrel in patients with severe renal insufficiency undergoing PCI for acute coronary syndrome. J Interv Cardiol. 2022, 2022:6476777. 10.1155\/2022\/6476777","journal-title":"J Interv Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.818215","article-title":"Comparison of clinical outcomes between Ticagrelor and Clopidogrel in acute coronary syndrome: a comprehensive meta-analysis","volume":"8","author":"Sun M","year":"2021","unstructured":"Sun M, Cui W, Li L. Comparison of clinical outcomes between Ticagrelor and Clopidogrel in acute coronary syndrome: a comprehensive meta-analysis. Front Cardiovasc Med. 2021, 8:818215. 10.3389\/fcvm.2021.818215","journal-title":"Front Cardiovasc Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.927582","article-title":"Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis","volume":"122","author":"Steg PG","year":"2010","unstructured":"Steg PG, James S, Harrington RA, et al.. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation. 2010, 122:2131-41. 10.1161\/CIRCULATIONAHA.109.927582","journal-title":"Circulation"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/FJC.0000000000000390","article-title":"Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention","volume":"68","author":"Tang X","year":"2016","unstructured":"Tang X, Li R, Jing Q, Wang Q, Liu P, Zhang P, Liu Y. Assessment of ticagrelor versus clopidogrel treatment in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. J Cardiovasc Pharmacol. 2016, 68:115-20. 10.1097\/FJC.0000000000000390","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2019.6447","article-title":"Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"180","author":"Turgeon RD","year":"2020","unstructured":"Turgeon RD, Koshman SL, Youngson E, Har B, Wilton SB, James MT, Graham MM. Association of ticagrelor vs clopidogrel with major adverse coronary events in patients with acute coronary syndrome undergoing percutaneous coronary intervention. JAMA Intern Med. 2020, 180:420-8. 10.1001\/jamainternmed.2019.6447","journal-title":"JAMA Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.4103\/0366-6999.239306","article-title":"Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention","volume":"131","author":"Wang HY","year":"2018","unstructured":"Wang HY, Li Y, Xu XM, Li J, Han YL. Impact of baseline bleeding risk on efficacy and safety of ticagrelor versus clopidogrel in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Chin Med J (Engl). 2018, 131:2017-24. 10.4103\/0366-6999.239306","journal-title":"Chin Med J (Engl)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.5114\/pwki.2015.55596","article-title":"Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls","volume":"11","author":"Winter MP","year":"2015","unstructured":"Winter MP, Kozi\u0144ski M, Kubica J, Aradi D, Siller-Matula JM. Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. Postepy Kardiol Interwencyjnej. 2015, 11:259-80. 10.5114\/pwki.2015.55596","journal-title":"Postepy Kardiol Interwencyjnej"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)62191-7","article-title":"Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study","volume":"23","author":"Cannon CP","year":"2010","unstructured":"Cannon CP, Harrington RA, James S, et al.. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010, 23:283-93. 10.1016\/S0140-6736(09)62191-7","journal-title":"Lancet"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d3527","article-title":"Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial","volume":"342","author":"James SK","year":"2011","unstructured":"James SK, Roe MT, Cannon CP, et al.. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011, 342:d3527. 10.1136\/bmj.d3527","journal-title":"BMJ"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1001\/jamacardio.2018.0612","article-title":"Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial","volume":"3","author":"Berwanger O","year":"2018","unstructured":"Berwanger O, Nicolau JC, Carvalho AC, et al.. Ticagrelor vs clopidogrel after fibrinolytic therapy in patients with ST-elevation myocardial infarction: a randomized clinical trial. JAMA Cardiol. 2018, 3:391-9. 10.1001\/jamacardio.2018.0612","journal-title":"JAMA Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/srep13789","article-title":"Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial","volume":"5","author":"Li P","year":"2015","unstructured":"Li P, Yang Y, Chen T, et al.. Ticagrelor overcomes high platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial. Sci Rep. 2015, 5:13789. 10.1038\/srep13789","journal-title":"Sci Rep"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-015-1183-9","article-title":"Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis","volume":"40","author":"Alexopoulos D","year":"2015","unstructured":"Alexopoulos D, Perperis A, Koniari I, et al.. Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. J Thromb Thrombolysis. 2015, 40:261-7. 10.1007\/s11239-015-1183-9","journal-title":"J Thromb Thrombolysis"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2014.07.001","article-title":"Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial)","volume":"15","author":"Winter JL","year":"2014","unstructured":"Winter JL, Lindefjeld DS, Veas N, et al.. Angiographic and electrocardiographic parameters of myocardial reperfusion in angioplasty of patients with ST elevation acute myocardial infarction loaded with ticagrelor or clopidogrel (MICAMI-TICLO trial). Cardiovasc Revasc Med. 2014, 15:284-8. 10.1016\/j.carrev.2014.07.001","journal-title":"Cardiovasc Revasc Med"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/190482-efficacy-and-safety-profile-of-ticagrelor-versus-clopidogrel-in-percutaneous-coronary-intervention-pci-for-acute-coronary-syndrome-acs-a-systematic-review-and-meta-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:07:38Z","timestamp":1707509258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/190482-efficacy-and-safety-profile-of-ticagrelor-versus-clopidogrel-in-percutaneous-coronary-intervention-pci-for-acute-coronary-syndrome-acs-a-systematic-review-and-meta-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.46455","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10,4]]}}}